Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 6/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | ATM | Q13315 | 1/20 | 0.60 |
| ▸ | MITF | O75030 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.58 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6325630 | 0.89 | HTT (0.56) | FFAR1LMNAATMALDH1A1TSHR | |
| SCHEMBL6324681 | 0.88 | FFAR1 (0.75) | FFAR1LMNAATMMITFTP53 | |
| SCHEMBL6327785 | 0.87 | LMNA (0.75) | FFAR1LMNAATMMITFTP53 | |
| SCHEMBL6326480 | 0.86 | MITF (0.74) | FFAR1LMNAATMMITFTP53 | |
| SCHEMBL6328594 | 0.84 | MITF (0.61) | FFAR1LMNAATMMITFTP53 | |
| SCHEMBL27608327 | 0.83 | ALDH1A1 (0.57) | FFAR1LMNAATMMITFTP53 | |
| SCHEMBL22419403 | 0.82 | ALDH1A1 (0.56) | FFAR1LMNAATMMITFTP53 | |
| SCHEMBL6324430 | 0.82 | MAPK1 (0.73) | FFAR1LMNAATMALDH1A1TSHR | |
| SCHEMBL6328183 | 0.81 | FFAR1 (0.58) | FFAR1LMNAATMMITFTP53 | |
| SCHEMBL6328269 | 0.81 | FFAR1 (0.61) | FFAR1LMNAATMMITFTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1423120-A4 | 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF | ICOS CORP (US) | 2005-12-28 | — | — | EP | disclosed |
| US-6924284-B2 | PARP inhibitors | ICOS CORPORATION (US) | 2005-08-02 | — | — | US | disclosed |
| EP-1423120-A1 | 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF | ICOS CORPORATION (US) | 2004-06-02 | — | — | EP | disclosed |
| US-20040087588-A1 | Parp inhibitors | ICOS CORPORATION | 2004-05-06 | — | — | US | disclosed |
| WO-2003015785-A1 | 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF | ICOS CORPORATION (US) | 2003-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087588-A1 | Parp inhibitors | PARP1, PARP2, PARP11 | FFAR1 2536/4885LMNA 448/4885ATM 414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.